Benjamin Hohl Sells 3,350 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl sold 3,350 shares of Enliven Therapeutics stock in a transaction that occurred on Friday, December 27th. The stock was sold at an average price of $22.15, for a total transaction of $74,202.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Benjamin Hohl also recently made the following trade(s):

• On Monday, December 30th, Benjamin Hohl sold 900 shares of Enliven Therapeutics stock. The shares were sold at an average price of $22.51, for a total value of $20,259.00.
• On Wednesday, November 27th, Benjamin Hohl sold 5,250 shares of Enliven Therapeutics stock. The stock was sold at an average price of $24.89, for a total value of $130,672.50.
• On Monday, October 28th, Benjamin Hohl sold 6,250 shares of Enliven Therapeutics stock. The shares were sold at an average price of $28.56, for a total value of $178,500.00.
• On Friday, October 18th, Benjamin Hohl sold 814 shares of Enliven Therapeutics stock. The stock was sold at an average price of $30.00, for a total transaction of $24,420.00.
• On Friday, October 4th, Benjamin Hohl sold 10,218 shares of Enliven Therapeutics stock. The shares were sold at an average price of $27.51, for a total transaction of $281,097.18.
• On Monday, October 7th, Benjamin Hohl sold 1,270 shares of Enliven Therapeutics stock. The stock was sold at an average price of $27.51, for a total transaction of $34,937.70.

Enliven Therapeutics Trading Up 6.2 %

Shares of Enliven Therapeutics stock opened at $23.90 on Friday. Enliven Therapeutics, Inc. has a twelve month low of $10.90 and a twelve month high of $30.03. The stock has a market cap of $1.17 billion, a price-to-earnings ratio of -12.58 and a beta of 1.02. The company has a fifty day moving average price of $25.09 and a 200 day moving average price of $24.28.

Institutional Investors Weigh In On Enliven Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of ELVN. Quest Partners LLC lifted its position in Enliven Therapeutics by 87.3% during the 2nd quarter. Quest Partners LLC now owns 1,592 shares of the company’s stock worth $37,000 after acquiring an additional 742 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its stake in shares of Enliven Therapeutics by 64.4% during the third quarter. China Universal Asset Management Co. Ltd. now owns 9,085 shares of the company’s stock valued at $232,000 after purchasing an additional 3,559 shares during the period. SG Americas Securities LLC acquired a new position in shares of Enliven Therapeutics during the third quarter worth $256,000. Verition Fund Management LLC purchased a new position in shares of Enliven Therapeutics in the third quarter valued at $271,000. Finally, The Manufacturers Life Insurance Company acquired a new stake in Enliven Therapeutics during the 2nd quarter valued at $322,000. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently commented on ELVN shares. BTIG Research assumed coverage on Enliven Therapeutics in a report on Friday, December 13th. They set a “buy” rating and a $42.00 price objective for the company. Robert W. Baird upped their price target on Enliven Therapeutics from $32.00 to $40.00 and gave the stock an “outperform” rating in a research note on Friday, November 15th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $37.00 price objective on shares of Enliven Therapeutics in a research note on Tuesday, October 1st. Four investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $38.25.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.